Outlook Therapeutics, Inc. (OTLK) Earnings History
Annual and quarterly earnings data from 2014 to 2025
Loading earnings history...
OTLK EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
OTLK Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 46.5% | -4744.3% | -4416.2% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export OTLK earnings history in CSV or JSON format
Free sign-in required to download data
Outlook Therapeutics, Inc. (OTLK) Earnings Overview
As of May 8, 2026, Outlook Therapeutics, Inc. (OTLK) reported trailing twelve-month net income of -$103M, reflecting +55.9% year-over-year growth. The company earned $-4.04 per diluted share over the past four quarters, with a net profit margin of -4416.2%.
Looking at the long-term picture, OTLK's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2014.
Outlook Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCKT (-$223M net income), ADVM (-$204M net income, -13092.7% margin), REPL (-$315M net income), OTLK has comparable earnings metrics. Compare OTLK vs RCKT →
OTLK Earnings vs Peers
Earnings metrics vs comparable public companies
OTLK Historical Earnings Data (2014–2025)
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$62M | +17.2% | -$67M | $-1.79 | -4416.2% | -4744.3% |
| 2024 | -$75M | -27.8% | -$72M | $-4.06 | - | - |
| 2023 | -$59M | +10.7% | -$53M | $-4.72 | - | - |
| 2022 | -$66M | -24.2% | -$63M | $-6.23 | - | - |
| 2021 | -$53M | -50.9% | -$52M | $-6.96 | - | - |
| 2020 | -$35M | -2.1% | -$37M | $-13.47 | - | - |
| 2019 | -$35M | -14.7% | -$36M | $-39.60 | -423.8% | -445.6% |
| 2018 | -$30M | +22.5% | -$30M | $-85.00 | -974.5% | -960.0% |
| 2017 | -$39M | +27.1% | -$36M | $-288.00 | -1019.1% | -941.2% |
| 2016 | -$53M | -12.5% | -$51M | $-587.20 | -1788.7% | -1723.1% |
See OTLK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OTLK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OTLK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOTLK — Frequently Asked Questions
Quick answers to the most common questions about buying OTLK stock.
Is OTLK growing earnings?
OTLK EPS is $-4.04, with earnings growth accelerating to +55.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-103M.
What are OTLK's profit margins?
Outlook Therapeutics, Inc. net margin is -4416.2%, with operating margin at -4744.3%. Below-average margins reflect competitive or cost pressures.
How consistent are OTLK's earnings?
OTLK earnings data spans 2014-2025. The accelerating earnings trend is +55.9% YoY. Historical data enables comparison across business cycles.